About the job
Alkeus Pharmaceuticals, Inc. is a pioneering clinical-stage biotechnology firm headquartered in Cambridge, Massachusetts, dedicated to the advancement of groundbreaking therapies aimed at addressing critical ocular diseases with significant unmet medical needs. Established in 2010, Alkeus has been diligently developing its flagship compound, gildeuretinol acetate (ALK-001), which has received designation as a breakthrough therapy and orphan drug status from the U. S. Food and Drug Administration. Gildeuretinol is currently being assessed across various clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) resulting from age-related macular degeneration (AMD), a leading cause of blindness in the United States.
Position Summary:
The Senior Clinical Scientist will take charge of providing scientific leadership and oversight for late-stage (Phase 3) clinical development programs focused on rare diseases in the field of ophthalmology. This role is crucial to maintaining scientific integrity, ensuring regulatory compliance, and successfully executing pivotal clinical trials necessary for global registration.
As a key individual contributor, the Senior Clinical Scientist will act as a primary scientific collaborator throughout the clinical development process, closely partnering with clinical operations, biostatistics, regulatory affairs, and safety teams to translate strategic objectives into high-quality Phase 3 studies. This position is ideally suited for a seasoned professional with a proven track record in late-stage clinical development, particularly in rare diseases and/or ophthalmology.

